ArticleHereditas2025
Hsa_circ_0006837 suppresses gastric cancer cell proliferation, migration, and invasion via the modulation of miR-424-5p.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mechanism by which circRERE (hsa_circ_0006837) modulates the malignant progression of gastric cancer was investigated to identify a novel biomarker and therapeutic target for this disease.
methodsHsa_circ_0006837 expression in GC tissues and cells was detected by RT-qPCR. Several data analysis methods were used to evaluate the significance of dysregulated hsa_circ_0006837 in GC. The patients were followed up for five years, and survival analysis was conducted using Kaplan-Meier curves. Cox regression was subsequently performed to analyze the risk factors for prognosis. The malignant behaviors of the cells were detected by the CCK-8 and Transwell assays. The relationship between hsa_circ_0006837 and miR-424-5p was assessed by conducting Spearman correlation analysis and verified by dual-luciferase reporter assay.
resultsHsa_circ_0006837 expression decreased in patients with GC, indicating a poorer patient prognosis. In GC cells, hsa_circ_0006837 overexpression suppressed malignant behaviors. Mechanistically, miR-424-5p was identified as a target of hsa_circ_0006837. The overexpression of miR-424-5p partially counteracted the suppressive effects of upregulated hsa_circ_0006837 on the malignant behaviors of GC cells. FBXO21 was identified as a downstream gene of the hsa_circ_0006837/miR-424-5p axis.
conclusionsTo summarize, hsa_circ_0006837 is a biomarker for the prognosis of GC. Mechanistically, hsa_circ_0006837 overexpression can modulate the malignant behaviors of GC cells through miR-424-5p.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.